What is the evidence base for Melanotan II?

Melanotan II's evidence base sits at mechanistic + off-label. The references on this page summarise 1 primary publication supporting the principal mechanism and applications. Where Phase II or Phase III human data exists for related indications, it is cited; where evidence is preclinical or limited to small case series, that is noted. The sourcing / quality / procurement interpretation respects the actual evidence tier rather than over-stating mechanistic plausibility.

What is the standard dosing protocol for Melanotan II?

Conventional Melanotan II dosing is 0.25-0.5 mg daily during loading, then 1-2x weekly via subq/intranasal. For sourcing and quality-control use specifically, the cycle pattern is typically 8–12 weeks on followed by a 4 week off-period. Higher doses are studied in advanced protocols but produce diminishing dose-response in the published literature.

What is the regulatory status of Melanotan II?

Melanotan II regulatory status: Unapproved in the United States; WADA status not on prohibited list; research level mechanistic + off-label. Clinical access for off-label use is via compounded prescription where permissible. International regulatory status varies by jurisdiction. For sourcing and quality-control use specifically, the regulatory profile shapes which monitoring and supervision approaches are required.

What are the safety considerations for Melanotan II?

Nausea (especially early), spontaneous erections in men, marked appetite suppression, hyperpigmentation. Watch new moles closely. Avoid in melanoma history. For sourcing and quality-control use, additional considerations: baseline labs appropriate to the targeted system, mid-cycle re-check at 4–6 weeks, and end-of-cycle full re-evaluation. Melanotan II's ~30 min pharmacokinetic profile and subq/intranasal administration route influence the side-effect profile in predictable ways.

How does Melanotan II's half-life affect dosing?

Melanotan II has a plasma half-life of ~30 min, which is short enough to require multiple daily doses to maintain therapeutic exposure. The receptor occupancy curve under daily during loading, then 1-2x weekly dosing at 0.25-0.5 mg per dose explains the typical onset timeline for sourcing and quality-control endpoints.

What are the procurement red flags for Melanotan II?

Six markers to evaluate when sourcing Melanotan II: lot-specific COAs available; HPLC purity ≥98% confirmed; mass spec confirming 1024 Da; endotoxin testing for SubQ-route material; physical address and regulatory disclosure on vendor site; cold-chain shipping options. Multiple missing markers = walk away. Pharmaceutical-grade compounded material is the lowest-risk supply path where accessible.

Home/ Compounds/ Melanotan II

Melanotan II

Sourcing Guide

Sourcing Melanotan II from research-grade vendors requires the QC framework that governs any peptide procurement: certificate of analysis review, lot-specific verification, third-party laboratory issuance, and — critically — endotoxin testing for injectable material. The cyclic α-MSH analogue with MC4R activity — tanning effects plus the sexual-response effects that led to its derivative bremelanotide (PT-141). The three-tier vendor market (pharmaceutical-grade compounded, reputable research-grade, grey-market) is described below.

Sourcing / Quality / Procurement Applications

Cold ChainVendor ComparisonBAC Water SourcingHPLC PurityCOA Review

Key Takeaways

Procurement lens: Melanotan II sourcing requires lot-specific COA, HPLC purity ≥98%, mass spec confirmation matching 1024 Da.
Mechanism: Non-selective melanocortin receptor agonist (MC1, MC3, MC4, MC5).
Storage: lyophilised at -20°C for 18-24 months; reconstituted at 4°C for 14-28 days.
Vendor tier: pharmaceutical-grade compounded > reputable research-grade > grey-market (3-5x cost differential; quality differential substantially larger).
Sourcing-validated stack partners: BPC-157, TB-500, GHK-Cu.

Sourcing / Quality / Procurement Mechanism

For procurement of Melanotan II, the relevant QC framework covers analytical purity (HPLC), structural identity (mass spec), microbiological safety (endotoxin), and stoichiometric correctness where applicable. Non-selective melanocortin receptor agonist (MC1, MC3, MC4, MC5). MC1R drives pigmentation; MC4R drives appetite suppression and sexual response; MC3R/5R contribute to energy expenditure and sebaceous secretion. Cyclic structure resists enzymatic degradation. The subsections below address each QC layer and the vendor-tier landscape.

Vendor tier comparison and price discipline

Three vendor tiers operate in the Melanotan II market: pharmaceutical-grade compounded prescription (physician-supervised, full COA, ICP-MS where relevant, highest cost), reputable research-chemical vendors (full COA, lot-specific, mid-tier cost), and grey-market unverified sources (template or absent COA, unverifiable supply chain, lowest cost). The price differential between tiers is roughly 3–5x; the quality differential is substantially larger and concentrated in the bottom tier.

HPLC purity and analytical identity

Minimum acceptable HPLC purity for Melanotan II is ≥98% in research-grade material. Mass spec confirmation should show the characteristic m/z of 1024 (M+H)+. Contaminant peaks above 1% in the HPLC trace warrant quantification on the COA and — ideally — structural identification of the major impurities.

COA evaluation and red flags

Acceptable Melanotan II certificates of analysis specify: (1) lot number matching the vial, (2) HPLC purity with chromatographic trace, (3) mass spec confirmation, (4) endotoxin testing for SubQ-route use, and (5) issuance from an accredited third-party laboratory. Template COAs that cannot be traced to a specific lot, COAs missing endotoxin data for injectable material, and COAs issued by the vendor's own laboratory rather than a third party are all sourcing red flags.

Sourcing / Quality / Procurement Applications

Red Flag Detection

Pharmaceutical-grade compounded Melanotan II is the lowest-risk sourcing path for red flag detection use where the route permits, particularly for users with clinical supervision. Research-grade material from accredited vendors is the practical alternative; grey-market sourcing is not appropriate for this application.

Vendor Comparison

For users targeting vendor comparison, the sourcing question is whether the chosen vendor consistently delivers analytical-spec material across lots. Repeated re-orders from the same vendor with mid-cycle COA spot-checks is the procurement pattern that catches lot drift before it affects results.

GMP vs Research Grade

Sourcing Melanotan II for gmp vs research grade use requires the same QC discipline as any peptide procurement: lot-specific COA, HPLC purity ≥98%, mass spec confirmation, endotoxin testing for injectable routes. Application-specific use does not relax the sourcing standard.

Storage Protocol

Pharmaceutical-grade compounded Melanotan II is the lowest-risk sourcing path for storage protocol use where the route permits, particularly for users with clinical supervision. Research-grade material from accredited vendors is the practical alternative; grey-market sourcing is not appropriate for this application.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	SubQ	0.25-0.5 mg	8–12 weeks on / 4 weeks off
Conservative starter	SubQ	1.25-0.5 mg	4–6 weeks initial cycle
Sourcing Guide focus	SubQ	0.25-0.5 mg	Daily during loading, then 1-2x weekly
Maintenance phase	SubQ	1.25-0.5 mg	Ongoing with periodic pauses

Dose timing for Melanotan II is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

Melanotan II stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from experienced peptide buyers.

Melanotan II + BPC-157: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Pairs naturally with Melanotan II's mechanism in sourcing / quality / procurement protocols.
Melanotan II + TB-500: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Pairs naturally with Melanotan II's mechanism in sourcing / quality / procurement protocols.
Melanotan II + GHK-Cu: GHK chelates copper(II) and acts as a transcriptional modulator: published microarray data show it influences over 4,000 human genes including resetting expression patterns toward younger cellular phenotypes. Pairs naturally with Melanotan II's mechanism in sourcing / quality / procurement protocols.
Melanotan II + Ipamorelin: Highly selective GHSR1a agonist. Pairs naturally with Melanotan II's mechanism in sourcing / quality / procurement protocols.

Safety & Regulatory Status

WADA: Not on prohibited list FDA: Unapproved Research: Mechanistic + off-label

Nausea (especially early), spontaneous erections in men, marked appetite suppression, hyperpigmentation. Watch new moles closely. Avoid in melanoma history.

Lens-specific safety considerations for sourcing / quality / procurement use of Melanotan II: Nausea (especially early), spontaneous erections in men, marked appetite suppression, hyperpigmentation. Watch new moles closely. Avoid in melanoma history. Additional sourcing / quality / procurement monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

Melanotan analogues and melanocortin receptor pharmacology

PMID 1429592

Melanotan II vs Related Peptides

Compound	Profile	Onset	Best For
Melanotan II	Cyclic α-MSH analogue	~30 min	Sourcing Guide
BPC-157	Stable gastric pentadecapeptide	~4 hr (oral)	Accelerated tendon, ligament, and gut tissue repair via VEGFR2-driven angiogenesis and FAK-paxillin signalling
TB-500	Synthetic thymosin β4 fragment	~2-3 days	A 17-amino-acid synthetic fragment of thymosin β4 with actin-sequestering activity — drives cell migration, tissue repair, and broad regenerative effects
GHK-Cu	Tripeptide-copper complex	~30 min plasma	A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression
Ipamorelin	Selective GHRP / ghrelin mimetic	~2 hr	The most selective ghrelin-receptor agonist among the GHRPs — stimulates GH release with minimal effect on cortisol, prolactin, or appetite

Frequently Asked Questions

Storage protocol?

Lyophilised: −20°C for 18–24 months. Reconstituted with bacteriostatic water: 4°C for 14–28 days. Avoid freeze-thaw cycles of reconstituted material. Cold-chain shipping is preferred for purchases; insulated packaging without active cooling is acceptable for shorter transit windows.

Lot variability across orders?

Even reputable vendors show some lot-to-lot variability. The QC-disciplined practice is to spot-check a fresh COA against the prior lot when re-ordering, and to track perceived response across lots. Substantial drift in subjective effects on a stable dose with a stable protocol often traces back to material quality rather than physiology.

Reconstitution best practices?

Use sterile bacteriostatic water (0.9% benzyl alcohol). Inject the BAC water down the side of the vial, not directly onto the lyophilised powder. Allow gentle dissolution; do not shake vigorously — swirl the vial. Label the reconstituted vial with concentration and date.

Vendor red flags?

Six markers: (1) no lot-specific COAs available, (2) HPLC purity only, no copper or stoichiometry assay where applicable, (3) no physical address or regulatory disclosure, (4) no cold-chain shipping option, (5) no refund policy for failed-QC lots, (6) therapeutic claims about research material. Multiple flags = walk away.

What is Melanotan II?

Melanotan II (also known as MT-II) is a 7-residue cyclic α-msh analogue with a molecular weight of 1024 Da and a plasma half-life of ~30 min. Non-selective melanocortin receptor agonist (MC1, MC3, MC4, MC5). MC1R drives pigmentation; MC4R drives appetite suppression and sexual response; MC3R/5R contribute to energy expenditure and sebaceous secretion. Cyclic structure resists enzymatic degradation. The compound is studied primarily in the sourcing / quality / procurement domain for the applications outlined above.

Is Melanotan II safe during pregnancy or breastfeeding?

Melanotan II, like most non-approved peptide therapeutics, does not have safety data supporting use during pregnancy or lactation. The default position is contraindication during pregnancy, lactation, and active conception, with discontinuation at least 2–3 cycles before planned conception. Approved indications (where they exist) may have specific guidance — verify with the prescribing physician.

Clinical Protocol

Start a Melanotan II Protocol

Alukard provides GMP-certified physician-supervised sourcing with GMP-certified Melanotan II and Pharmaceutical-grade compounds with full COA documentation.

Get Protocol

Quick Facts

Molecular weight: 1024 Da
Sequence length: 7 aa
Half-life: ~30 min
WADA: Not on prohibited list
FDA: Unapproved
Research: Mechanistic + off-label

Stack Partners

BPC-157

TB-500

GHK-Cu

Ipamorelin

Semax

Research Note

All sourcing / quality / procurement applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for Melanotan II unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

GMP-certified physician-supervised sourcing

Start Your Sourcing / Quality / Procurement Protocol for Melanotan II

Alukard provides GMP-certified physician-supervised sourcing with Pharmaceutical-grade compounds with full COA documentation.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised